Sinergium Biotech welcomes the MPP and the WHO

During 24-26 October, we had the privilege of hosting a visit from the Medicines Patent Pool (MPP) as part of the mRNA Technology Transfer Programme. This visit marked a significant step in our ongoing efforts to strengthen our capabilities in the field of mRNA technology.

The objectives of this visit encompassed several key areas:
Facility Assessment: Our visitors assessed the current state of our plant, gaining a comprehensive understanding of our facilities, quality control systems, equipment, personnel, and regulatory compliance.
Strategy Analysis: A rigorous analysis of Sinergium’s strategy for implementing mRNA technology was conducted, focusing on the steps taken to establish and advance on our mRNA platform.
Action Plan Development: A crucial outcome of this visit is the collaborative development of an action plan. This plan will outlines specific activities, budget allocations, and timelines, all aimed at ensuring that Sinergium is well-prepared to receive and implement mRNA technology effectively.

Our team remains dedicated to becoming the leading mRNA vaccine producer in Argentina. The knowledge and insights gained from this visit are invaluable in helping us achieve this goal. We extend our gratitude to the Medicines Patent Pool (MPP) for their support and guidance throughout this endeavor.

You can learn more about this Programme by visiting the following links:

About SINERGIUM Biotech – Argentine biopharmaceutical company is specialized in the research, development, production and commercialization of vaccines and highly complex biopharmaceutical products.

About MPP – The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries.

To see published note click here.


Recent posts

Back    |   See all